DexCom (NASDAQ:DXCM) EVP Sadie Stern Sells 2,565 Shares

Key Points

• DexCom EVP Sadie Stern sold 2,565 shares at an average price of $88.37, generating $226,669.05. The Rule 10b5-1 transaction reduced her holdings by 1.99%, leaving her with 126,043 shares.
• DexCom shares rose to $90.82, near the company’s 52-week high of $92.59. The company recently reported quarterly EPS of $0.70 and revenue of $1.31 billion, exceeding analyst estimates, with revenue up 13.1% year over year.
• Analysts maintain a broadly positive outlook, with the stock carrying a consensus “Moderate Buy” rating and an average price target of $88.71. Institutional investors own 97.75% of DexCom’s outstanding shares.

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) EVP Sadie Stern sold 2,565 shares of the stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $88.37, for a total value of $226,669.05. Following the completion of the sale, the executive vice president owned 126,043 shares in the company, valued at $11,138,419.91. This trade represents a 1.99% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Price Performance

DexCom stock traded up $1.53 during midday trading on Friday, hitting $90.82. 2,544,135 shares of the company's stock were exchanged, compared to its average volume of 5,235,547. The company has a market cap of $34.27 billion, a P/E ratio of 35.90, a PEG ratio of 1.50 and a beta of 1.41. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73. The stock has a 50-day moving average price of $78.84 and a two-hundred day moving average price of $71.47. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $92.59.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.61 by $0.09. The firm had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The company's revenue for the quarter was up 13.1% on a year-over-year basis. During the same quarter last year, the company posted $0.48 EPS. On average, equities research analysts forecast that DexCom, Inc. will post 2.64 earnings per share for the current year.

Hedge Funds Weigh In On DexCom

Institutional investors and hedge funds have recently bought and sold shares of the stock. Brighton Jones LLC grew its holdings in shares of DexCom by 257.7% in the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company's stock worth $1,290,000 after purchasing an additional 11,946 shares during the last quarter. Integrated Wealth Concepts LLC boosted its position in DexCom by 6.3% during the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company's stock valued at $227,000 after buying an additional 196 shares during the period. Empowered Funds LLC grew its stake in shares of DexCom by 5.4% in the first quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company's stock worth $577,000 after purchasing an additional 436 shares during the last quarter. Focus Partners Wealth increased its stake in shares of DexCom by 13.2% during the first quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company's stock valued at $493,000 after buying an additional 841 shares during the period. Finally, NewEdge Advisors LLC increased its position in DexCom by 1.4% during the 2nd quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company's stock valued at $1,681,000 after purchasing an additional 258 shares during the period. 97.75% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

DXCM has been the subject of a number of research analyst reports. Benchmark lifted their price objective on shares of DexCom from $77.00 to $82.00 and gave the stock a "buy" rating in a report on Friday, July 31st. BTIG Research reaffirmed a "buy" rating and set a $90.00 price target (up from $80.00) on shares of DexCom in a research note on Friday, July 31st. William Blair upgraded DexCom to a "strong-buy" rating in a research report on Friday, May 15th. TD Cowen reissued a "buy" rating on shares of DexCom in a report on Friday, July 31st. Finally, Bank of America cut their target price on DexCom from $100.00 to $80.00 and set a "buy" rating for the company in a research note on Monday, May 18th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $88.71.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source